Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Balance impairment in people with multiple sclerosis: Preliminary evidence for the Balance Evaluation Systems Test.
Changes to anti-JCV antibody levels in a Swedish national MS cohort.
Substance Name: Amiloride
MS-SMART: Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial
The potential role of epigenetic modifications in the heritability of multiple sclerosis.
Single-use autoinjector for peginterferon-β1a treatment of relapsing-remitting multiple sclerosis: safety, tolerability and patient evaluation data from the Phase IIIb ATTAIN study.
Effect of lipoic acid consumption on oxidative stress among multiple sclerosis patients: A randomized controlled clinical trial.
Adherence to, and effectiveness of, subcutaneous interferon β-1a administered by RebiSmart® in patients with relapsing multiple sclerosis: results of the 1-year, observational SMART study.
Stress signaling etches heritable marks on chromatin.
Combined central and peripheral demyelination: Clinical features, diagnostic findings, and treatment.
Positive year one results from Biogen Idec's Phase 3 advance trial of PLEGRIDY™ (peginterferon beta-1a) presented at AAN meeting
The history of the oxazaphosphorine cytostatics.
Modeling probability of additional cases of natalizumab-associated JCV sero-negative progressive multifocal leukoencephalopathy.
Guillain-Barré syndrome: clinical profile and management.
Interferon beta 1b following natalizumab discontinuation: one year, randomized, prospective, pilot trial.
Rare variants in the CYP27B1 gene are associated with multiple sclerosis.
Increase in NF-κB-sensitive miRNA-146a and miRNA-155 in multiple sclerosis (MS) and pro-inflammatory neurodegeneration.
Asymptomatic lung disease caused by Mycobacterium kansasii as an opportunistic infection in a patient treated with natalizumab for relapsing-remitting multiple sclerosis.
RGC-32 as a potential biomarker of relapse and response to treatment with glatiramer acetate in multiple sclerosis.
Induction of pathogenic TH17 cells by inducible salt-sensing kinase SGK1.
Diminished Th17 (not Th1) responses underlie multiple sclerosis disease abrogation after hematopoietic stem cell transplantation.
Long-term safety and efficacy of teriflunomide: Nine-year follow-up of the randomized TEMSO study.
Peripheral accumulation of newly produced T and B lymphocytes in natalizumab-treated multiple sclerosis patients.
Clinical and MRI characterization of MS patients with a pure and severe cognitive onset.
Lipocalin 2 is present in the EAE brain and is modulated by natalizumab.

Pages